Amgen, Inc. (AMGN) Earns “Overweight” Rating from Morgan Stanley
Amgen, Inc. (NASDAQ:AMGN)‘s stock had its “overweight” rating restated by equities research analysts at Morgan Stanley in a research report issued to clients and investors on Wednesday.
Other institutional investors have added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Amgen by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 44,916,785 shares of the medical research company’s stock valued at $7,291,342,000 after buying an additional 953,984 shares during the last quarter. Wellington Management Group LLP raised its position in Amgen by 16.0% in the first quarter. Wellington Management Group LLP now owns 13,544,922 shares of the medical research company’s stock valued at $2,030,789,000 after buying an additional 1,864,688 shares during the last quarter. Morgan Stanley raised its position in Amgen by 5.4% in the fourth quarter. Morgan Stanley now owns 7,317,025 shares of the medical research company’s stock valued at $1,187,772,000 after buying an additional 373,979 shares during the last quarter. Norges Bank acquired a new position in Amgen during the fourth quarter valued at about $1,071,028,000. Finally, Geode Capital Management LLC raised its position in Amgen by 2.1% in the first quarter. Geode Capital Management LLC now owns 6,444,273 shares of the medical research company’s stock valued at $964,334,000 after buying an additional 132,632 shares during the last quarter.
Amgen, Inc. (NASDAQ:AMGN)‘s stock had its “overweight” rating restated by equities research analysts at Morgan Stanley in a research report issued to clients and investors on Wednesday.
Other institutional investors have added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Amgen by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 44,916,785 shares of the medical research company’s stock valued at $7,291,342,000 after buying an additional 953,984 shares during the last quarter. Wellington Management Group LLP raised its position in Amgen by 16.0% in the first quarter. Wellington Management Group LLP now owns 13,544,922 shares of the medical research company’s stock valued at $2,030,789,000 after buying an additional 1,864,688 shares during the last quarter. Morgan Stanley raised its position in Amgen by 5.4% in the fourth quarter. Morgan Stanley now owns 7,317,025 shares of the medical research company’s stock valued at $1,187,772,000 after buying an additional 373,979 shares during the last quarter. Norges Bank acquired a new position in Amgen during the fourth quarter valued at about $1,071,028,000. Finally, Geode Capital Management LLC raised its position in Amgen by 2.1% in the first quarter. Geode Capital Management LLC now owns 6,444,273 shares of the medical research company’s stock valued at $964,334,000 after buying an additional 132,632 shares during the last quarter.